The U. S. Food and Drug Administration has approved a
7/16/2008
Top Stories
- Bone Marrow Transplant Offers Glimmer of Hope for AIDS Cure
- Women's and Men's Hands Differ in Bacteria Count The surprising bit of news is that women carry more types on average than men.
- Toasting another healthy benefit of red wine may help prevent fat accumulation in the liver
- mentally taxing job's may help protect against the memory loss
- it’s flu and cold season. If you’re feeling under the weather—wash your hands.
- high altitude mountain climbing may not be the best thing for your brain.
- A new study says that eating a western diet accounts for more than a third of heart attacks worldwide.
- If you’re a woman and you have a few extra cavities blame your hormones
- Lumpectomy not advised if breast cancer returns A mastectomy is prudent when breast cancer returns after a lumpectomy, because survival rates are be...
- 10% of American children have an undiagnosed eye problem If not treated, eye trouble can lead to difficulties in school and even loss of vision.
The U. S. Food and Drug Administration has approved a genetic test to help determine if breast cancer patients would benefit from the drug Herceptin.
The new test calculates how many copies of the HER-2 gene are present in cancer cells.
Approximately 20 to 30 percent of breast cancers over-express the H E R–2 gene. These tumors tend to grow faster and are generally more likely to recur.
The drug Herceptin targets the H E R-2 protein to help stop the growth of cancer cells.
The new test calculates how many copies of the HER-2 gene are present in cancer cells.
Approximately 20 to 30 percent of breast cancers over-express the H E R–2 gene. These tumors tend to grow faster and are generally more likely to recur.
The drug Herceptin targets the H E R-2 protein to help stop the growth of cancer cells.